Investment
Features
FeesSafety
Academy
More
Pluang+

NRXP's KETAFREE shows potential for commercial success pending FDA approval, making NRXP a speculative buy.

Analyst Insights
14 Sep 2026
Seeking Alpha
View Source
Bullish
NRXP's KETAFREE shows potential for commercial success pending FDA approval, making NRXP a speculative buy.

NRx Pharmaceuticals (NRXP) is developing KETAFREE, a ketamine-based treatment that could become a commercial success if it gains FDA approval. The company also benefits from its clinical infrastructure through HOPE Therapeutics, despite currently having a small revenue base. Additional drug candidates like NRX-101 and partnerships such as with GeNeuro provide further growth options. Although NRXP faces a tight cash runway, its valuation holds long-term upside potential, leading to a speculative buy recommendation.

NRx Pharmaceuticals and its ketamine-based treatment development are the focus of this update, with Pluang providing a snapshot of the Health sector market as of Sep 14, 2026 20:12 WIB. Among 91 priced Health-sector US stocks tradable on Pluang, 53 rose and 28 fell today. Notable movers include SMMT (Summit Therapeutics Inc) at USD 18.24 with a 3.93% increase, CTXR (Citius Pharmaceuticals Inc) at USD 0.60 up 3.75%, and MDT (Medtronic PLC) at USD 94.25 rising 3.62%.

More News

Senteon wins Best Patch and Configuration Management award at 2026 Top InfoSec Innovator Awards

Senteon wins Best Patch and Configuration Management award at 2026 Top InfoSec Innovator Awards

Senteon was awarded the Best Solution Patch and Configuration Management at the 2026 Top InfoSec Innovator Awards by Cyber Defense Magazine. The company’s platform automates endpoint hardening and continuously monitors security configurations to redu...

Others
Neutral
3 hours ago
RENK sells slide bearings business to Miba, focusing on defense sector growth.

RENK sells slide bearings business to Miba, focusing on defense sector growth.

RENK Group AG has sold its slide bearings business to Austrian company Miba AG to sharpen its focus on the defense sector, aiming to increase defense-related revenue to 90% by 2030. The sale does not affect RENK's Marine & Industry civilian business,...

Company Fundamentals
Bullish
3 hours ago
RENK sells its slide bearings business to Miba to focus on defense sector growth

RENK sells its slide bearings business to Miba to focus on defense sector growth

RENK Group AG is selling its slide bearings business to Austrian company Miba AG as part of a strategic shift to focus more on its defense sector. The sale supports RENK's plan to increase defense-related revenue to about 90% by 2030, while the civil...

Company Fundamentals
Bullish
3 hours ago
RENK sells Slide Bearings business to Miba AG, focusing more on defense sector.

RENK sells Slide Bearings business to Miba AG, focusing more on defense sector.

RENK Group AG, through its subsidiary RENK GmbH, has signed a binding agreement to sell its Slide Bearings business to Austria's Miba AG. The Slide Bearings segment produces standardized bearings used mainly in industrial and civil markets. This sale...

Company Fundamentals
Neutral
4 hours ago
RENK sells its Slide Bearings business to Miba AG, focusing more on defense sector.

RENK sells its Slide Bearings business to Miba AG, focusing more on defense sector.

RENK Group AG, through its subsidiary RENK GmbH, has signed a binding agreement to sell its Slide Bearings business to Austria's Miba AG. This unit produces slide bearings mainly used in industrial and civilian markets. The sale aligns with RENK's 20...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App